Walmart asks Flipkart to defer IPO, focus on EBITDA breakeven by FY27: report (WMT:NASDAQ)May 15, 2026
Share Facebook Twitter LinkedIn Pinterest Email Bionano Genomics outlines 2025 revenue guidance of $29M-$32M with strategic focus on utilization
Walmart asks Flipkart to defer IPO, focus on EBITDA breakeven by FY27: report (WMT:NASDAQ)May 15, 2026